NCT02901054 is a NA clinical trial of Ondansetron in Pain, sponsored by Washington University School of Medicine.

Who is sponsoring NCT02901054?

NCT02901054 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT02901054?

Interventions in NCT02901054: Ondansetron.

Is NCT02901054 still recruiting?

NCT02901054 is currently completed. Last updated 27 December 2019.

Are results published for NCT02901054?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-12-27 · How we verify

NCT02901054

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CSF Pharmacokinetics of Ondansetron

Completed NA Results posted Last updated 27 December 2019

What this trial tests

NA trial testing Ondansetron in Pain in 19 participants. Completed in 17 November 2016.

Timeline

25 August 2016

Primary endpoint
17 November 2016

17 November 2016

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	19
Start date	25 August 2016
Primary completion	17 November 2016
Estimated completion	17 November 2016
Sites	1 location across United States

Drugs / interventions tested

Ondansetron (ondansetron) — full drug profile →

Conditions studied

Pain — all drugs for Pain →

Sponsor

Washington University School of Medicine

Who can join

Adults 18 to 70, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

CSF to Plasma Concentration Ratio Primary · 0-180 min from the beginning of infusion

CSF: plasma ratio of ondansetron at the time of obtaining the CSF sample

Group	Value	95% CI
Open Label Infusion Ondansetron	0.15	± 0.05

Sponsor's own description

Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability that may affect that distribution. Study procedures will include iv ondansetron administration, serial blood draws, cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans.
Chiang MD, Frey K, Lee C, Kharasch ED, et al · · 2021 · cited 7× · PMID 32495990 · DOI 10.1111/bcp.14412

Verify or expand the search:

Other trials of Ondansetron

Trials testing the same drug.

NCT06861010 — Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatograp · Phase 3 · recruiting
NCT07310563 — A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obe · Phase 1 · completed
NCT06898268 — Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux · NA · completed
NCT06475846 — A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults · Phase 2 · completed
NCT06390787 — The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics · Phase 2, PHASE3 · completed

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02901054 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 27 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02901054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing